CONTEXT: Neuropathic pain is common, disabling, and often difficult to treat. OBJECTIVES: To compare guideline-based drug management with Scrambler therapy, a patient-specific electrocutaneous nerve stimulation device. METHODS: A clinical trial with patients randomized to either guideline-based pharmacological treatment or Scrambler therapy for a cycle of 10 daily sessions was performed. Patients were matched by type of pain including postsurgical neuropathic pain, postherpetic neuralgia, or spinal canal stenosis. Primary outcome was change in visual analogue scale (VAS) pain scores at one month; secondary outcomes included VAS pain scores at two and three months, pain medication use, and allodynia. RESULTS:Fifty-two patients were randomized. The mean VAS pain score before treatment was 8.1 points (control) and 8.0 points (Scrambler). At one month, the mean VAS score was reduced from 8.1 to 5.8 (-28%) in the control group, and from 8 to 0.7 points (-91%) in the Scrambler group (P<0.0001). At two and three months, the mean pain scores in the control group were 5.7 and 5.9 points, respectively, and 1.4 and 2 points in the Scrambler group, respectively (P<0.0001). More relapses were seen in polyradicular pain than monoradicular pain, but retreatment and maintenance therapy gave relief. No adverse effects were observed. CONCLUSION: In this pilot randomized trial, Scrambler therapy appeared to relieve chronic neuropathic pain better than guideline-based drug management.
RCT Entities:
CONTEXT: Neuropathic pain is common, disabling, and often difficult to treat. OBJECTIVES: To compare guideline-based drug management with Scrambler therapy, a patient-specific electrocutaneous nerve stimulation device. METHODS: A clinical trial with patients randomized to either guideline-based pharmacological treatment or Scrambler therapy for a cycle of 10 daily sessions was performed. Patients were matched by type of pain including postsurgical neuropathic pain, postherpetic neuralgia, or spinal canal stenosis. Primary outcome was change in visual analogue scale (VAS) pain scores at one month; secondary outcomes included VAS pain scores at two and three months, pain medication use, and allodynia. RESULTS: Fifty-two patients were randomized. The mean VAS pain score before treatment was 8.1 points (control) and 8.0 points (Scrambler). At one month, the mean VAS score was reduced from 8.1 to 5.8 (-28%) in the control group, and from 8 to 0.7 points (-91%) in the Scrambler group (P<0.0001). At two and three months, the mean pain scores in the control group were 5.7 and 5.9 points, respectively, and 1.4 and 2 points in the Scrambler group, respectively (P<0.0001). More relapses were seen in polyradicular pain than monoradicular pain, but retreatment and maintenance therapy gave relief. No adverse effects were observed. CONCLUSION: In this pilot randomized trial, Scrambler therapy appeared to relieve chronic neuropathic pain better than guideline-based drug management.
Authors: Paolo Notaro; Carlo Alberto Dell'Agnola; Alessandro J Dell'Agnola; Alessio Amatu; Katia Bruna Bencardino; Salvatore Siena Journal: Support Care Cancer Date: 2015-09-26 Impact factor: 3.603
Authors: Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith Journal: Support Care Cancer Date: 2019-06-17 Impact factor: 3.603
Authors: Maureen A Mealy; Sharon L Kozachik; Lawrence J Cook; Lauren Totonis; Ruth Andrea Salazar; Jerilyn K Allen; Marie T Nolan; Thomas J Smith; Michael Levy Journal: Neurology Date: 2020-04-08 Impact factor: 9.910